AbbVie and Neurocrine Biosciences have reported positive results from two replicate pivotal Phase III clinical trials of Elagolix to treat premenopausal women suffering from endometriosis.

Endometrosis is a condition when cells that normally line up the uterus begin to grow outside of the uterus resulting in chronic pelvic pain, pain during intercourse and increased pain during menses.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Elagolix is an orally administered, short-acting molecule and has been developed as a gonadotropin-releasing hormone (GnRH) receptor antagonist.

It inhibits the endogenous GnRH signalling by fusing competitively to GnRH receptors in the pituitary gland.

“Elagolix is an orally administered, short-acting molecule and has been developed as a gonadotropin-releasing hormone (GnRH) receptor antagonist.”

Its administration results in rapid, reversible, dose-dependent inhibition of luteinising hormone (LH) and follicle-stimulating hormone (FSH) secretion, leading to reduced ovarian production of the sex hormones, estradiol and progesterone, during therapy.

The two Phase III M12-665 and M12-671 trials were conducted as a randomised, double-blind, placebo-controlled study, which were aimed at testing the safety and efficacy of Elagolix while examining 1,700 women with moderate-to-severe endometriosis-associated pain.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Results of the studies suggested the efficacy of Elagolix over placebo in reducing menstrual pain (dysmenorrhea, DYS) and non-menstrual pelvic pain (NMPP) associated with endometriosis.

It was determined on the basis of Daily Assessment of Endometriosis Pain scale.

Elagolix has also demonstrated a safety profile, which was consistent with the previously conducted studies.

AbbVie development vice-president and chief medical officer Rob Scott said: “These results from the largest clinical trials ever conducted in endometriosis support AbbVie’s continued efforts to pursue regulatory filing of Elagolix as a potential new treatment option for the disease’s most prevalent symptoms.

“There have been few recent scientific advancements for patients suffering from endometriosis and physicians are in need of additional treatment options to help manage this chronic and painful disease.”